Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.
Lampa J, Nordström D, van Vollenhoven R, Lund Hetland M, Haavardsholm EA, Østergaard M, Rudin A, Heiberg MS, Nurmohamed M, Gudbjornsson B, Lend K, Hørslev-Petersen K, Sokka-Isler T, Gröndal G, Krabbe S, Lindqvist J, Gjertsson I, Glinatsi D, Kapetanovic M, Gentline C, Aga AB, Relas H, Lorenzen T, Cagnotto G, Back J, Hendricks O, Dijkshoorn B, Öberg K, Ljoså MK, Brodin E, Lindegaard HM, Söderbergh A, Rizk M, Kastbom A, Larsson P, Uhrenholt L, Just SA, Stevens DJ, Laurberg TB, Bakland G, Olsen IC, Sexton J, Uhlig T; NORD-STAR study group.
Lampa J, et al. Among authors: heiberg ms.
Lancet Rheumatol. 2026 Apr;8(4):e285-e294. doi: 10.1016/S2665-9913(26)00007-X.
Lancet Rheumatol. 2026.
PMID: 41881637
Clinical Trial.